Ovarian cancer is a malignant tumor with a high mortality rate in women. PARP inhibitors (poly ADP-ribose polymerase inhibitors, PARPi), as one of the mainstays of maintenance therapy, can significantly improve the survival rate of patients; however, with the widespread use of PARPi, PARPi resistance has become an urgent problem in the treatment process. Current studies have found that metabolic reprogramming in the tumor microenvironment (TME) may affect chemoresistance in ovarian cancer through multiple mechanisms, but whether lipid metabolic reprogramming in the TME is involved in the formation of PARPi resistance is not clear. The aim of this paper is to explore the effect of lipid metabolism in TME on PARPi resistance in ovarian cancer in recent years and to analyze the possible link between it and PARPi resistance, with a view to providing new perspectives for further understanding the mechanism of PARPi resistance formation and searching for new therapeutic targets.